79 related articles for article (PubMed ID: 18673425)
1. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy.
Hofmann WP; Kronenberger B; Bojunga J; Stamm B; Herrmann E; Bücker A; Mihm U; von Wagner M; Zeuzem S; Sarrazin C
J Viral Hepat; 2008 Nov; 15(11):790-6. PubMed ID: 18673425
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.
Redondo-Cerezo E; Casado-Caballero F; Martin-Rodriguez JL; Hernandez-Quero J; Escobar-Jimenez F; Gonzalez-Calvin JL
Osteoporos Int; 2014 Jun; 25(6):1709-15. PubMed ID: 24676843
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.
Megahed A; Salem N; Fathy A; Barakat T; Alsayed MAEL; Mabood SAE; Zalata KR; Abdalla AF
World J Pediatr; 2017 Aug; 13(4):346-352. PubMed ID: 28130750
[TBL] [Abstract][Full Text] [Related]
4. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
[TBL] [Abstract][Full Text] [Related]
5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
Gur A; Dikici B; Nas K; Bosnak M; Haspolat K; Sarac AJ
BMC Gastroenterol; 2005 Sep; 5():30. PubMed ID: 16171525
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
Butt AS; Mumtaz K; Aqeel I; Shah HA; Hamid S; Jafri W
Trop Gastroenterol; 2009; 30(4):207-12. PubMed ID: 20426280
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
von Wagner M; Hofmann WP; Teuber G; Berg T; Goeser T; Spengler U; Hinrichsen H; Weidenbach H; Gerken G; Manns M; Buggisch P; Herrmann E; Zeuzem S
Hepatology; 2008 Nov; 48(5):1404-11. PubMed ID: 18846541
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
16. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
[TBL] [Abstract][Full Text] [Related]
17. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
19. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.
Martinot-Peignoux M; Comanor L; Minor JM; Ripault MP; Pham BN; Boyer N; Castelnau C; Giuily N; Hendricks D; Marcellin P
J Viral Hepat; 2006 Oct; 13(10):701-7. PubMed ID: 16970602
[TBL] [Abstract][Full Text] [Related]
20. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
